Skip to main content
. 2023 Feb 28;13:1111146. doi: 10.3389/fonc.2023.1111146

Figure 2.

Figure 2

Case 1. (A) Bulky recurrence on the vertex of cSCC at cycle 1 (C1) of cemiplimab; (B) partial response at C23 of cemiplimab and C4 of sonidegib; (C) stable disease at C30 of cemiplimab and C10 of sonidegib. (D) Infiltrative BCC extended to the right external auditory meatus at C18 of cemiplimab and C1 of sonidegib; (E) partial response at C23 of cemiplimab and C4 of sonidegib; (F) complete response of BCC at C30 of cemiplimab and C10 of sonidegib.